Loft, N D
Skov, L
Iversen, L
Gniadecki, R
Dam, T N
Brandslund, I
Hoffmann, H J
Andersen, M R
Dessau, R B
Bergmann, A C
Andersen, N M
Andersen, P S
Bank, S
Vogel, U
Andersen, V
Article History
Received: 21 November 2016
Revised: 17 May 2017
Accepted: 26 May 2017
First Online: 11 July 2017
Competing interests
: Dr Skov has received consultancy and/or speaker honoraria from Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme (MSD) and LEO Pharma and is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, MSD, Eli Lilly, Celgene and Novartis. Dr Iversen has been a paid speaker for MSD, Pfizer, AbbVie, Almirall, Janssen-Cilag, Eli Lilly, Novartis and LEO Pharma. He has been consulting or serving on expert/advisory boards with Pfizer, AbbVie, Almirall, BMS, Janssen-Cilag, Novartis, Eli Lilly, LEO Pharma and MSD. He has served as investigator for MSD, Pfizer, AbbVie, Janssen-Cilag, Eli Lilly, Novartis, Amgen and LEO Pharma and has received research and educational grant from Pfizer, AbbVie, Novartis, MSD and LEO Pharma. Dr Gniadecki has received consultancy and speaker honoraria from Abbvie, Janssen-Cilag and Novartis and is a member of the advisory boards of Abbvie, Amgen, Janssen-Cilag, Eli Lilly, Celgen, Novartis and Therakos. Dr Dam has received compensation as a speaker and member of an advisory board for Janssen-Cilag and Abbvie. Dr Andersen has received compensation as a consultant and member of an advisory board for MSD and Janssen-Cilag.